Pharmasset, Inc.
303-A College Road East
Princeton,
NJ 08540
Phone: 609-613-4100
Fax: 609-613-4150
Web Site: http://www.pharmasset.com
| Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection; and Racivir for the treatment of human immunodeficiency virus (HIV) infection. The company has three product candidates under development, which include RG7128, a HCV nucleoside polymerase inhibitor that is in Phase IIb clinical trial; PSI-7851, a HCV nucleotide polymerase inhibitor that completed Phase I clinical trial; and Racivir, which completed Phase II clinical trial, for the treatment of HIV. It has strategic collaboration agreement with F. Hoffmann-LaRoche Ltd. and Hoffmann-La Roche Inc. for the development of PSI-6130 and its products, including RG7128. The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; Emory University; Bukwang Pharm. Co., Ltd; University of Georgia Research Foundation, Inc. and Yale University; and Boehringer Ingelheim Chemicals, Inc. Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Mr. P. Schaefer Price M.B.A., 47
Chief Exec. Officer, Pres
|
$
625.00K |
$
0 |
Mr. Kurt Leutzinger C.P.A, M.B.A., 58
Chief Financial Officer, Principal Accounting Officer and Exec. VP
|
$
364.00K |
$
0 |
Dr. Michael J. Otto PH.D., 61
Chief Scientific Officer and Exec. VP of Pharmaceutical Research
|
$
328.00K |
$
752.00K |
Dr. M. Michelle Berrey MD, MPH., 43
Chief Medical Officer
|
$
396.00K |
$
0 |
Mr. Paul Lubetkin Esq., 59
Exec. VP , Sec. and Gen. Counsel
|
$
312.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
0.40 (1.80%) 
Profile
